A validated liquid chromatography-tandem mass spectroscopy method for the quantification of tolinapant in human plasma.
Journal
Analytical science advances
ISSN: 2628-5452
Titre abrégé: Anal Sci Adv
Pays: Germany
ID NLM: 9918334986206676
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
24
03
2022
revised:
23
05
2022
accepted:
23
05
2022
medline:
4
6
2022
pubmed:
4
6
2022
entrez:
8
5
2024
Statut:
epublish
Résumé
Tolinapant (ASTX660), a pan-selective inhibitor of apoptosis protein antagonist with dual cIAP/XIAP activity, was identified as a clinical candidate in preclinical efficacy, pharmacokinetic and safety studies. In order to assess tolinapant in first-in-human Phase I/II clinical trials, a validated bioanalytical method was required to determine plasma pharmacokinetics. Tolinapant and d
Identifiants
pubmed: 38716121
doi: 10.1002/ansa.202200009
pii: ANSA202200009
pmc: PMC10989545
doi:
Types de publication
Journal Article
Langues
eng
Pagination
198-204Informations de copyright
© 2022 The Authors. Analytical Science Advances published by Wiley‐VCH GmbH.
Déclaration de conflit d'intérêts
The authors have declared no conflict of interest.